Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Gene therapy in primary immunologic failure].

S S Frøland1

  • 1Seksjon for klinisk immunologi og infeksjonsmedisin, Medisinsk avdeling Rikshospitalet 0027 Oslo.

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|March 13, 2001
PubMed
Summary

Gene therapy shows promise for primary immunodeficiency diseases (PID). Recent successes in treating severe combined immunodeficiency (SCID) offer hope, though challenges remain for broader PID gene therapy applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduced immunoglobulin levels in epilepsy patients treated with levetiracetam, lamotrigine, or carbamazepine.

Acta neurologica Scandinavica. Supplementum·2012
Same author

Enhanced levels of CCL19 in patients with advanced acquired immune deficiency syndrome (AIDS).

Clinical and experimental immunology·2012
Same author

Persistently raised plasma levels of platelet-derived inflammatory mediators in HIV-infected patients during highly active anti-retroviral therapy.

Journal of thrombosis and haemostasis : JTH·2011
Same author

Professor emeritus Jacob B. Natvig, one of the founders of Scandinavian journal of immunology, turns 75.

Scandinavian journal of immunology·2009
Same author

Chemokines and common variable immunodeficiency; possible contribution of CCL19, CCL21 and CCR7 to immune dysregulation.

Clinical and experimental immunology·2009
Same author

CXCL16 in HIV infection - a link between inflammation and viral replication.

European journal of clinical investigation·2009

Area of Science:

  • Genetics and immunology
  • Rare disease research
  • Therapeutic innovation

Context:

  • Primary immunodeficiency diseases (PID) are rare congenital disorders.
  • Genetic defects impair immune system function, leading to severe infections.
  • Current treatments are limited, with bone marrow transplantation as a potential cure.

Purpose:

  • To review gene therapy protocols and clinical trial reports for PID.
  • To assess the current status and future potential of gene therapy in treating PID.
  • To identify challenges and opportunities in applying gene therapy to PID.

Summary:

  • Gene therapy trials are underway for various PID types.
  • A significant advancement includes successful gene therapy for two infants with severe combined immunodeficiency (SCID).

Related Experiment Videos

  • No definitive cures for PID using gene therapy have been documented yet.

    • Impact:

    • Gene therapy offers substantial future potential for treating multiple PID types.
    • Overcoming obstacles in human gene therapy and immune system complexity is crucial.
    • Successful SCID treatment highlights gene therapy's viability for specific immunodeficiencies.